The Section on Translational Neuroscience of NICHD seeks parties interested in licensing and/or collaborative research to co-develop this therapeutic management of Menkes Disease and related copper transport disorders.
The technology is directed to the use of single-stranded RNA overhangs or toeholds of varying lengths (< 12 nucleotides) contained in nucleic acid-based nanoparticles which trigger the association of these nanoparticles and activates multiple functionalities such as gene silencing and/or cell-specific targeting. The use of RNA toeholds is superior to that of DNA toeholds in that it allows for smaller nanoparticles (fewer nucleotides for the toeholds) resulting in greater chemical stability, less immunogenic and higher yield of production. The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations for use of RNA overhangs or toeholds in nucleic acid nanoparticles.
This technology provides improved processes for production and purification of nucleic acid-containing compositions, such as non-naturally occurring viruses, for example, recombinant polioviruses that can be employed as oncolytic agents. Some of the improved processes relate to improved processes for producing viral DNA template.
Researchers at the National Cancer Institute (NCI) RNA Biology Laboratory have developed nanoparticles that can deliver an agent (i.e., therapeutic or imaging) and release the agent upon targeted photoactivation allowing for controlled temporal and localized release of the agent.
Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (“NICHD”), seek CRADA partner or collaboration for development of agents to treat multiple sclerosis or other conditions associated with myelin remodeling by administering an agent that inhibits cleavage of Neurofascin 155 or Caspr1. The agent could be a thrombin inhibitor, an agent that inhibits thrombin expression, an anti-thrombin antibody that specifically inhibits thrombin mediated cleavage of Neurofascin 155, a mutated version or fragment of Neurofascin 155 or Caspr1, or antibodies to Neurofascin 155 or Caspr1.
The National Institute on Aging, Laboratory of Clinical Investigation, is seeking parties interested in collaborative research to co-develop ketamine metabolites for the treatment of different forms of depression and for alleviating pain.
The technology is a series of modafinil analogues that bind with moderate to high affinity to the dopamine (DA) transporter (DAT). Some compounds also have affinity for the serotonin (5-HT) transporter (SERT) and/or sigma-1 receptor. The compounds retain the desired dopamine transporter affinity with greater metabolic stability over previously described unsubstituted piperazine ring analogues. Importantly, these compounds have no predicted addictive liability. Also disclosed are methods for treating substance use disorders as well as other neuropsychiatric disorders such as ADHD, depression, narcolepsy, and cognitive impairment. Researchers at the National Institute on Drug Abuse (NIDA) seek licensing and/or co-development research collaborations for further development and commercialization of the compounds.
The National Institute on Drug Abuse’s Medicinal Chemistry Section seeks partners interested in collaborative research to co-develop analogues of modafinil for the treatment of drug abuse and sleep and attention disorders.